Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 22, 2026

Apr. 22, 2026

Clinical Skills Institute Launches $900 Fast-Track Medical Assistant Program Under $1,000

Indeterminate EIN Presswire

Apr. 22, 2026

Result.Law Releases Medical Bill Dispute Tool to Help Patients Exercise Rights Under the No Surprises Act

Indeterminate EIN Presswire

Apr. 22, 2026

UHI Medical Clinic Marks Earth Day with New Commitments to Advance Sustainable Outpatient Care using My Green Doctor

Indeterminate EIN Presswire

Apr. 22, 2026

Shriners Children’s Names World-Renowned Pediatric Surgeon Scott H. Kozin M.D. as Chief Medical Officer

Indeterminate EIN Presswire

Apr. 22, 2026

Biz4Group LLC Emerges as a Top AI Healthcare Solutions Provider, Setting New Benchmarks in the U.S. Healthcare Industry

Indeterminate EIN Presswire

Apr. 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Indeterminate GlobeNewswire

Apr. 22, 2026

Same-Day Smiles Seamless Experience: Miami Patients Are Now Getting Dental Crowns in Just Hours at Sharp Dentistry

Indeterminate EIN Presswire

Apr. 22, 2026

H2Ocean Supports Duke Cancer Institute’s 'Healing from Head and Neck Cancer' Event, Advancing Patient Survivorship Care

Indeterminate EIN Presswire

Apr. 22, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Indeterminate GlobeNewswire

Apr. 22, 2026

Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée

Indeterminate GlobeNewswire

Apr. 22, 2026

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire

Apr. 22, 2026

SetPoint Medical and Lovell Government Services Partner to Expand Access to Innovative Rheumatoid Arthritis Therapy

Indeterminate EIN Presswire

Apr. 22, 2026

George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage

Indeterminate GlobeNewswire

Apr. 22, 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Indeterminate GlobeNewswire

Apr. 22, 2026

Sight Sciences Announces the Release of its Sustainability Report

Indeterminate GlobeNewswire

Apr. 22, 2026

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Apr. 22, 2026

Altimmune Announces Proposed Underwritten Public Offering of Securities

Indeterminate GlobeNewswire

Apr. 22, 2026

Working with AI to Find the Best Treatment Options

Indeterminate EIN Presswire

Apr. 22, 2026

Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5

Indeterminate GlobeNewswire

Apr. 22, 2026

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

Indeterminate GlobeNewswire